IMRXBullishpreclinical efficacy data presented at SITC 2026news
Medium materiality6/10
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
Nov 6, 2026, 9:41 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
If replicated in humans, these preclinical efficacy signals could expand atebimetinib's clinical development opportunities and potential future revenue from combination indications; however, translation from mouse models to clinical benefit is uncertain and requires human trial data.
AI summary
What happened, with direct paths to the underlying reporting
Immuneering reported SITC 2026 preclinical data showing atebimetinib + anti-PD1 cured 50% of mice in a RAS-mutant colorectal model and nearly doubled survival in a RAS-mutant lung model.
Atebimetinib combinations with anti-PD1 cured 50% of mice in a RAS-mutant colorectal cancer model.
Atebimetinib combinations with anti-PD1 nearly doubled survival in a RAS-mutant lung cancer model.
These new preclinical data were presented at SITC 2026.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
